Immix Biopharma Inc

NASDAQ IMMX

Data sourced from

and

Download Data

Immix Biopharma Inc Free Cash Flow for the year ending December 31, 2023: USD -11.42 M

Immix Biopharma Inc Free Cash Flow is USD -11.42 M for the year ending December 31, 2023, a -54.20% change year over year. Free Cash Flow is the cash flow available to a company after deducting capital expenditures from operating cash flow, indicating its ability to generate cash for expansion, debt repayment, or dividends.

Immix Biopharma Inc Free Cash Flow for the year ending December 31, 2022 was USD -7.41 M, a -365.90% change year over year.
Immix Biopharma Inc Free Cash Flow for the year ending December 31, 2021 was USD -1.59 M, a -292.92% change year over year.
Immix Biopharma Inc Free Cash Flow for the year ending December 31, 2020 was USD -404.69 K, a 49.24% change year over year.
Immix Biopharma Inc Free Cash Flow for the year ending December 31, 2019 was USD -797.34 K.

NASDAQ: IMMX

Immix Biopharma Inc

CEO	Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
IPO Date	Dec. 16, 2021
Location	United States
Headquarters	11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
Employees	14
Sector	Healthcare
Industry	Biotechnology

Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Key trends